Individuals with type 2 diabetes
newly prescribed a sodium-glucose cotransporter-2 (SGLT2
have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study published online in the Annals of Internal Medicine
Dr Michael Fralick, M.D., Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues compared the rate of gout
between adults prescribed an SGLT2 inhibitor
and those prescribed a GLP1 receptor agonist in a population-based new-user cohort study; data were included for 295,907 adults. Patients with type 2 diabetes
newly prescribed an SGLT2 inhibitor
were propensity score-matched to those newly prescribed a GLP1 agonist.
The medical researchers found that the incidence of gout
was lower among patients prescribed an SGLT2 inhibitor
versus those prescribed a GLP1 agonist (4.9 versus 7.8 events per 1,000 person-years), with a hazard ratio of 0.64 and a rate difference of −2.9 per 1,000 person-years.
Dr Fralick told Thailand Medical
News via a phone interview, "Future studies are necessary to confirm our findings, and if replicated, SGLT2 inhibitors
might be an effective class of medication for the prevention of gout
for patients with diabetes
or metabolic disorders.”
Two authors from the research team disclosed financial ties to the pharmaceutical industry.
Reference : Fralick M, Chen SK, Patorno E, et al. Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020; [Epub ahead of print 14 January 2020]. doi: https://doi.org/10.7326/M19-2610